An Overview of Types, Diagnosis, and Treatment

Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis. 

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

The ABCDE Rule of Recognition

The ABCDE Rule of Recognition

Early detection of melanoma is the most critical factor in survival. To aid in identifying suspicious lesions, the dermatological community developed the ABCDE rule. This mnemonic guides patients and physicians in evaluating pigmented lesions for signs of malignancy.

A is for Asymmetry: Benign moles are typically symmetrical; if you were to draw a line through the middle, the two halves would match. Melanomas are often asymmetrical, with one half unlike the other.

B is for Border: Benign moles usually have smooth, even borders. Melanomas often have irregular, scalloped, or poorly defined edges. The pigment may appear to leak into the surrounding skin.

C is for Color: Benign moles are usually a single shade of brown. Melanomas frequently exhibit color variegation, displaying multiple shades of black, brown, tan, and sometimes patches of white, gray, red, or blue.

D is for Diameter: While melanomas can be tiny, a lesion larger than 6 millimeters (about the size of a pencil eraser) warrants closer inspection. However, many melanomas are diagnosed when they are smaller than this.

E is for Evolving: This is arguably the most crucial criterion. Any mole that is changing in size, shape, color, or elevation, or that is causing new symptoms such as bleeding, itching, or crusting, is suspicious.

While the ABCDE rule is a powerful tool, it does not capture every melanoma. Nodular melanomas, for instance, may be symmetrical and have even borders, but are dangerous because of their rapid vertical growth (Evolving). Therefore, any persistent or changing skin lesion requires professional evaluation.

  • Asymmetry refers to the lack of mirror-image balance in the lesion.
  • Irregular, notched, or blurred borders suggest malignancy.
  • Color variation within a single lesion is a high-risk sign.
  • A diameter greater than 6mm indicates a need for evaluation.
  • Evolution or change over time is the most sensitive indicator.
Icon LIV Hospital

The “Ugly Duckling” Sign

The “Ugly Duckling” Sign

In addition to evaluating individual lesions, the “Ugly Duckling” sign is a comparative method used to identify melanoma. Most individuals produce moles that look somewhat similar to one another; this is the patient’s “signature nevus” pattern. For example, one person might have small, dark moles, while another has larger, lighter moles.

The Ugly Duckling sign posits that a melanoma will stand out because it looks different from the patient’s other moles. It is the outlier. If a patient has many large, light moles and one small, dark mole, the small dark one is the Ugly Duckling. Conversely, if a patient has many small dark moles and one large, pale mole, the large one is the outlier.

This concept is beneficial for patients with dysplastic nevus syndrome, who may have hundreds of atypical-looking moles. Rather than biopsying every irregular mole, dermatologists look for the one that breaks the pattern. This contextual analysis improves diagnostic accuracy and helps identify lesions that might not strictly follow the ABCDE criteria but are biologically distinct from the background benign nevi.

  • Patients typically exhibit a consistent pattern in their benign moles.
  • The Ugly Duckling is the lesion that deviates from this pattern.
  • Outliers may be darker, lighter, larger, or smaller than surrounding nevi.
  • Contextual comparison aids in patients with high mole counts.
  • Identifying the outlier improves the detection of subtle melanomas.
Icon 1 LIV Hospital

Ultraviolet Radiation: The Primary Carcinogen

Ultraviolet Radiation: The Primary Carcinogen

The overwhelming majority of cutaneous melanomas are caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources, such as tanning beds. UV radiation is divided into UVA and UVB. UVB rays are shorter-wavelength, higher-energy rays that cause sunburn. They directly damage DNA. UVA rays are longer and penetrate deeper into the dermis, contributing to skin aging and indirect DNA damage via oxidative stress. Both play a role in melanomagenesis.

The pattern of exposure matters significantly. For melanoma, intermittent, intense sun exposure leading to blistering sunburns—especially during childhood and adolescence—is the most substantial risk factor. This contrasts with non-melanoma skin cancers, which are more strongly linked to chronic, cumulative exposure over a lifetime. However, chronic exposure can cause specific subtypes, such as lentigo maligna melanoma.

Artificial tanning beds are a potent source of carcinogenic radiation. They emit UVA radiation at intensities many times higher than the midday sun. Use of tanning beds before age 35 significantly increases the risk of melanoma. The World Health Organization classifies UV radiation from tanning devices as a Group 1 carcinogen, placing it in the same risk category as tobacco and asbestos.

  • UVB radiation causes direct DNA damage and sunburns.
  • UVA radiation penetrates deeply into the skin and induces oxidative stress.
  • Blistering childhood sunburns are a critical risk factor.
  • Intermittent, intense exposure drives most melanoma subtypes.
  • Tanning beds provide concentrated carcinogenic exposure.

Phenotypic and Genetic Risk Factors

Phenotypic and Genetic Risk Factors

Certain physical traits, or phenotypes, are inherently associated with a higher risk of melanoma. These traits generally relate to the skin’s ability to protect itself from UV radiation. Individuals with Fitzpatrick Skin Types I and II—those with fair skin, light eyes (blue or green), and red or blonde hair—are at the most significant risk. These individuals produce more pheomelanin (a red/yellow pigment) and less eumelanin (a brown/black pigment). Pheomelanin is less effective at blocking UV radiation and can even generate free radicals when exposed to sunlight, further damaging cells.

Genetic mutations also play a role. Approximately 10 percent of melanomas occur in families with a hereditary predisposition. The most common high-risk gene mutation is in CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A). This gene creates proteins that regulate cell division. When mutated, the brakes on cell growth are removed. Families with CDKN2A mutations often have multiple members affected by melanoma and may also be prone to pancreatic cancer.

Other genetic factors include mutations in the MC1R gene, which is responsible for red hair and fair skin. Even in individuals without red hair, carrying MC1R variants can increase melanoma risk by altering pigment production and DNA repair efficiency. Additionally, having a high number of benign moles (more than 50) or the presence of atypical (dysplastic) nevi is a strong phenotypic marker for increased risk.

  • Fair-skinned individuals produce less protective eumelanin.
  • Pheomelanin can promote oxidative damage upon UV exposure.
  • CDKN2A mutations drive hereditary melanoma syndromes.
  • MC1R gene variants increase risk independent of hair color.
  • High nevus count is a strong predictor of melanoma risk.

Immunosuppression and Environmental Factors

A robust immune system is essential for detecting and destroying abnormal cells before they develop into overt cancer. Consequently, individuals with compromised immune systems are at elevated risk for melanoma. This includes organ transplant recipients who must take lifelong immunosuppressive medications to prevent rejection. These patients have a higher incidence of melanoma and, crucially, a higher risk of the cancer behaving aggressively and metastasizing.

Similarly, patients with HIV/AIDS or lymphoproliferative disorders are at increased risk. The immune surveillance theory suggests that the immune system constantly “edits” potential tumors; when this editing function is suppressed, malignant clones survive.

Beyond UV radiation, few environmental chemicals have been definitively linked to melanoma, though some studies suggest potential associations with heavy metals or pesticides in occupational settings. However, these associations are weak compared to the overwhelming influence of UV radiation. The primary environmental driver remains solar and artificial ultraviolet exposure.

  • Immune surveillance prevents the survival of malignant clones.
  • Organ transplant recipients face an elevated risk due to medication.
  • Immunosuppression correlates with more aggressive tumor behavior.
  • HIV/AIDS patients have compromised tumor defense mechanisms.
  • Environmental chemical risks are secondary to UV radiation.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Group 346 LIV Hospital

Reviews from 9,651

4,9

Was this article helpful?

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

FREQUENTLY ASKED QUESTIONS

What does an “evolving” mole look like?

An evolving mole is changing. This could mean it is growing wider or taller. It might change color, becoming darker, or develop new colors, such as red, white, or blue. It could also refer to a change in sensation, such as a mole that starts to itch, swell, or bleed without injury. Any change is a warning sign.

No. Tanning beds are actually more dangerous. They emit concentrated UVA radiation that can be up to 10-15 times stronger than the sun’s at midday. This intense radiation penetrates deep into the skin and causes severe damage to the DNA in skin cells, drastically increasing the risk of melanoma, mainly when used by young people.

Yes. As a melanoma grows, the cancer cells can disrupt the tiny blood vessels in the skin. This can cause the lesion’s surface to become fragile and bleed easily, sometimes with minimal friction or even spontaneously. Crusting or a sore that does not heal is also a sign of potential malignancy.

No. While people with darker skin have more natural protection against UV rays, they are not immune to melanoma. When melanoma occurs in darker skin, it often appears in areas not exposed to the sun, such as the palms of the hands, soles of the feet, or under the nails (Acral Lentiginous Melanoma). These are often diagnosed later, leading to worse outcomes.

Childhood and adolescence are periods of rapid cell growth and division in the skin. DNA damage from blistering sunburns during these sensitive windows can “program” the melanocytes for cancer later in life. The damage lies dormant for decades, but the genetic errors accumulated in youth set the stage for melanoma in adulthood.

Spine Hospital of Louisiana
Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 26 75

How helpful was it?

helpful
GDPR
helpful
GDPR
helpful
GDPR